Craft
  • Home
  •  / Dechra Pharmaceuticals
Dechra Pharmaceuticals

Dechra Pharmaceuticals

Revenue

£681.8 M

FY, 2022

Market Capitalization

£3 B

2022-11-21

Dechra Pharmaceuticals Summary

Company summary

Overview
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Our key focus therapeutic areas are: • Endocrinology • Dermatology • Anaesthesia and analgesia • Ophthalmology • Cardiovascular disease • Equine locomotion • Food producing animal antimicrobials • And pet diets
Type
Public
Status
Active
Founded
1997
HQ
Lostock Gralam, GB | view all locations
Website
http://www.dechra.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Paul Sandland

    Paul Sandland, Chief Financial Officer

  • Anthony Lucas

    Anthony Lucas, Group Director, Product Development

  • Ian Page

    Ian Page, Chief Executive Officer

  • Mike Eldred

    Mike Eldred, President North American Operations

LocationsView all

16 locations detected

  • Lostock Gralam, Northwich HQ

    United Kingdom

    24 Cheshire Avenue Cheshire Business Park

  • Leawood, KS

    United States

    7015 College Blvd #525

  • Melbourne, FL

    United States

    2571 W Eau Gallie Blvd

  • Dornbirn, Vorarlberg

    Austria

    Hintere Achmühlerstraße 1A

  • Pointe-Claire, Québec

    Canada

    1 Holiday Avenue, East Tower Suite 345

  • Uldum

    Denmark

    Mekuvej 9

and 10 others

Dechra Pharmaceuticals Financials

Summary financials

Revenue (FY, 2022)
£681.8M
Gross profit (FY, 2022)
£475.6M
Net income (FY, 2022)
£58.2M
Cash (FY, 2022)
£120.9M
EBIT (FY, 2022)
£102.3M
Enterprise value
$3.2B

Footer menu